Abstract

INTRODUCTION: Although decades of experimental and clinical research have shed a lot of light on the pathogenesis of Alzheimer's disease (AD), there are still a lot of questions that need to be answered. The current proliferation of open data-sharing initiatives that collect clinical, routine, and biological data from individuals with Alzheimer's disease presents a potentially boundless wealth of information about a condition.
 METHODS: While it is possible to hypothesize that there is no comprehensive collection of puzzle pieces, there is currently a proliferation of such initiatives. This abundance of data surpasses the cognitive capacity of humans to comprehend and interpret fully. In addition, the psychophysiology mechanisms underlying the whole biological continuum of AD may be investigated by combining Big Data collected from multi-omics studies. In this regard, Artificial Intelligence (AI) offers a robust toolbox for evaluating large, complex data sets, which might be used to gain a deeper understanding of AD. This review looks at the recent findings in the field of AD research and the possible obstacles that AI may face in the future.
 RESULTS: This research explores the use of CAD tools for diagnosing AD and the potential use of AI in healthcare settings. In particular, investigate the feasibility of using AI to stratify patients according to their risk of developing AD and to forecast which of these patients would benefit most from receiving personalized therapies.
 CONCLUSION: To improve these, fuzzy membership functions and rule bases, fuzzy models are trained using fuzzy logic and machine learning.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call